JM Forbes, LTL Yee, V Thallas, M Lassila, … - Diabetes, 2004 - Am Diabetes Assoc Advanced glycation end product (AGE) formation may contribute to the progression
of atherosclerosis, particularly in diabetes. The present study explored
atherosclerosis in streptozotocin-induced diabetic apolipoprotein ... Cited by 137 - Related articles - BL Direct - All 9 versions
- ►ahajournals.org LG Bucciarelli, T Wendt, W Qu, Y Lu, E Lalla … - Circulation, 2002 - Am Heart Assoc Methods and Results— Male apoE-null mice, age 6 weeks, were rendered diabetic
with streptozotocin or treated with citrate buffer. At age 14 weeks, certain
mice were killed or treated with once-daily murine soluble RAGE or albumin; ... Cited by 307 - Related articles - BL Direct - All 8 versions
- ►fasebj.org [PDF] JM Forbes, V Thallas, MC Thomas, HW … - The FASEB Journal, 2003 - FASEB Page 1. The FASEB Journal express article 10.1096/fj.02-1102fje. Published online
July 18, 2003. The breakdown of pre-existing advanced glycation end ... Cited by 127 - Related articles - BL Direct - All 5 versions
NL Alderson, ME Chachich, NN Youssef, RJ … - Kidney international, 2003 - nature.com In previous studies, pyridoxamine (PM) limited the formation of advanced
glycation end products (AGEs) and development of nephropathy in
streptozotocin-diabetic rats without affecting glycemic control. However, ... Cited by 94 - Related articles - BL Direct - All 7 versions
- ►ahajournals.org R Candido, JM Forbes, MC Thomas, V Thallas, … - Circulation research, 2003 - Am Heart Assoc The formation of advanced glycation end products (AGEs) on extracellular matrix
components leads to accelerated increases in collagen cross linking that
contributes to myocardial stiffness in diabetes. This study determined the ... Cited by 211 - Related articles - BL Direct - All 8 versions
R Candido, TJ Allen, M Lassila, Z Cao, V … - Circulation, 2004 - Am Heart Assoc Methods and Results— Diabetes was induced by injection of streptozotocin in
6-week-old apoE-null mice. Diabetic animals were randomized to no treatment,
irbesartan, or amlodipine for 20 weeks. Diabetes was associated with an ... Cited by 126 - Related articles - BL Direct - All 7 versions
PJ Thornalley - Archives of Biochemistry and Biophysics, 2003 - Elsevier Aminoguanidine (AG) is a prototype therapeutic agent for the prevention of
formation of advanced glycation endproducts. It reacts rapidly with
α,β-dicarbonyl compounds such as methylglyoxal, glyoxal, and ... Cited by 125 - Related articles - All 4 versions
- ►ahajournals.org R Candido, KA Jandeleit-Dahm, Z Cao… - Circulation, 2002 - Am Heart Assoc Background— Atherosclerosis is a major complication of diabetes, but the
mechanisms by which diabetes promotes macrovascular disease have not been fully
delineated. Although several animal studies have demonstrated that ... Cited by 165 - Related articles - BL Direct - All 10 versions
TP Degenhardt, NL Alderson, DD Arrington, … - Kidney international, 2002 - chem.sc.edu Department of Chemistry and Biochemistry, Animal Resource Facility, and School
of Medicine, University of South Carolina, Columbia, South Carolina, and
Department of Laboratory Medicine, University of Minnesota School of ... Cited by 193 - Related articles - BL Direct - All 6 versions
WK Bolton, DC Cattran, ME Williams, SG Adler, … - Am J Nephrol, 2004 - content.karger.com Background/Aims: Pimagedine inhibits the formation of advanced glycation end
products and slows the progression of diabetic complications in experimental
models. This study was undertaken to determine if pimagedine ameliorates ... Cited by 127 - Related articles - BL Direct - All 6 versions
